Most of the data and abstracts have been dispensed as Day 1 of ASCO21 uncovered, with many more in the pipeline. Have a sneak peek at some of the crucial abstracts picked by DelveInsight that covered the latest innovations happening in Breast cancer as demonstrated at ASCO21.
Abstract 517_monarchE Study (abemaciclib combined with ET demonstrated a clinically meaningful treatment benefit in IDFS and DRFS)
Eli Lilly and Company presented the data from the positive Phase 3 monarchE trial evaluating Verzenio, a CDK4/6 inhibitor, in a subgroup of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high-risk early breast cancer (EBC) who had received neoadjuvant chemotherapy (NAC).
The data showed that the patients with HR+, HER2- EBC who received NAC were noted to be at a higher risk of recurrence. In multivariable analysis, compared with patients who had ET alone, patients who received abemaciclib + ET had significantly better invasive disease-free survival (2-year survival, 87.2% vs 80.6%), and better distant relapse-free survival (2-year survival, 89.5% vs 82.8%). Also, abemaciclib combined with ET reduces the risk of developing an IDFS or a DRFS event. In addition, safety data were consistent with abemaciclib safety profile.
Considering that data of monarchE study, which showed that abemaciclib when given in addition to ET demonstrated a clinically meaningful treatment benefit in IDFS and DRFS, there are few positive oncologist reviews:
“The data from monarchE further confirm this higher risk based on the number of events that occurred in the control arm for this subset of patients,” Given the need for new treatments for high-risk early breast cancer, especially in this neoadjuvant population, it’s encouraging to see these impressive results with a 38% reduction in the risk of recurrence with the addition of Verzenio to standard endocrine therapy.
Abstract 1080_Trodelvy (sacituzumab govitecan/SG)_Patients with prior neoadjuvant/adjuvant chemotherapy in metastatic triple-negative breast cancer (mTNBC)_Immunomedics/Gilead Sciences
ASCENT Study: Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).
Immunomedics, a subsidiary of Gilead Sciences, happily shared the results of the subgroup analysis of brain metastasis negative patients who relapsed within 12 months of neoadjuvant or adjuvant therapy and received only one line of treatment for the metastatic disease before entering the ASCENT study. In the study, sacituzumab govitecan (SG) was compared to single-agent chemotherapy of physician's choice in the second-line or greater setting. The results of the trial showed that SG demonstrated a significantly longer progression-free survival of 5.6 vs. 1.7 months and a median overall survival advantage of 12.1 vs. 6.7 months. There was a manageable safety profile. Keeping the results in mind, treatment with SG demonstrated superior outcomes compared to chemotherapy in patients with metastatic triple-negative breast cancer who had received only one line of chemotherapy in the metastatic setting and had recurred in 12 months or less after neoadjuvant or adjuvant therapy. Hence the evidence shows SG as a good second-line option for patients with metastatic triple-negative breast cancer who have relapsed early and have had only one prior systemic therapy. With Trodelvy, Gilead continues to challenge the standard of care in locally advanced and metastatic TNBC.
Expert Views “Trodelvy was the first treatment to demonstrate a proven survival advantage in pre-treated patients with locally advanced or metastatic TNBC, and the analysis presented at ASCO 2021 reaffirms this benefit over standard of care with important new data in the second-line setting. The efficacy observed in the second-line metastatic setting with Trodelvy is highly meaningful, since many patients will progress quickly following chemotherapy."
Let's discuss more about the impact of presented studies on the Breast cancer market. Drop us an email at email@example.com.